Identification of *Plasmodium vivax* Proteins with Potential Role in Invasion Using Sequence Redundancy Reduction and Profile Hidden Markov Models

Daniel Restrepo-Montoya^{1,2,3,4}, David Becerra^{1,2}, Juan G. Carvajal-Patiño^{1,3,4}, Alvaro Mongui^{4¤}, Luis F. Niño^{1,2}, Manuel E. Patarroyo^{4,5}, Manuel A. Patarroyo^{3,4}*

1 Bioinformatics and Intelligent Systems Research Laboratory - BIOLISI, Universidad Nacional de Colombia, Bogotá D.C., Colombia, 2 Research Group on Combinatorial Algorithms - ALGOS-UN, Universidad Nacional de Colombia, Bogotá D.C., Colombia, 3 School of Medicine and Health Sciences, Universidad del Rosario, Bogotá D.C., Colombia, 4 Fundación Instituto de Inmunología de Colombia - FIDIC, Bogotá D.C., Colombia, 5 School of Medicine, Universidad Nacional de Colombia, Bogotá D.C., Colombia

Abstract

Background: This study describes a bioinformatics approach designed to identify *Plasmodium vivax* proteins potentially involved in reticulocyte invasion. Specifically, different protein training sets were built and tuned based on different biological parameters, such as experimental evidence of secretion and/or involvement in invasion-related processes. A profile-based sequence method supported by hidden Markov models (HMMs) was then used to build classifiers to search for biologically-related proteins. The transcriptional profile of the *P. vivax* intra-erythrocyte developmental cycle was then screened using these classifiers.

Results: A bioinformatics methodology for identifying potentially secreted *P. vivax* proteins was designed using sequence redundancy reduction and probabilistic profiles. This methodology led to identifying a set of 45 proteins that are potentially secreted during the *P. vivax* intra-erythrocyte development cycle and could be involved in cell invasion. Thirteen of the 45 proteins have already been described as vaccine candidates; there is experimental evidence of protein expression for 7 of the 32 remaining ones, while no previous studies of expression, function or immunology have been carried out for the additional 25.

Conclusions: The results support the idea that probabilistic techniques like profile HMMs improve similarity searches. Also, different adjustments such as sequence redundancy reduction using Pisces or Cd-Hit allowed data clustering based on rational reproducible measurements. This kind of approach for selecting proteins with specific functions is highly important for supporting large-scale analyses that could aid in the identification of genes encoding potential new target antigens for vaccine development and drug design. The present study has led to targeting 32 proteins for further testing regarding their ability to induce protective immune responses against *P. vivax* malaria.

Citation: Restrepo-Montoya D, Becerra D, Carvajal-Patiño JG, Mongui A, Niño LF, et al. (2011) Identification of *Plasmodium vivax* Proteins with Potential Role in Invasion Using Sequence Redundancy Reduction and Profile Hidden Markov Models. PLoS ONE 6(10): e25189. doi:10.1371/journal.pone.0025189

Editor: Leonardo Mariño-Ramírez, National Institutes of Health, United States of America

Received July 8, 2011; Accepted August 29, 2011; Published October 3, 2011

Copyright: © 2011 Restrepo-Montoya et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors would like to extend their sincerest gratitude to Asociación de Investigación Solidaria (SADAR), Caja Navarra (Navarra, Spain) and Agencia Española de Cooperación Internacional para el Desarrollo for supporting and financing this project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: mapatarr.fidic@gmail.com

¤ Current address: Corporación Corpogen, Bogotá D.C., Colombia

Introduction

Human malaria is caused by five parasite species from the genus *Plasmodium*, of which *Plasmodium falciparum* has a preferential distribution in African countries and is particularly important, since it produces most of the fatal cases. The second species in clinical importance for humans is *Plasmodium vivax* (predominantly distributed throughout Asia and America). *P. vivax* does not cause such an imminent life-threatening condition as that caused by *P. falciparum*; however, it imposes an important social and economic toll on the world's poorest countries, as reflected in the large number of disability adjusted life years (DALYs) associated with its

incidence [1]. Furthermore, several aspects still hamper the total eradication of this disease, which include (1) the gradual emergence of antimalarial drug resistance among parasite strains, as well as (2) insecticide-resistant populations of the malaria mosquito vector, and (3) the lack of an effective vaccine [2].

Progress in *P. vivax* research has been notably delayed by contrast with *P. falciparum*, partly due to the difficulty of establishing a long-term *in vitro* culture of this species given that it is restricted to invading human reticulocytes which only account for $\sim 1-2\%$ of circulating red blood cells. This difficulty has been reflected in the delayed release of its genome sequence [3], the transcriptional profile of its intra-erythrocyte developmental cycle

[4] and the partial proteome of its schizont stage [5] compared to the release of the same studies in *P. falciparum. In silico* approaches have emerged from such experimental limitations, thereby promoting the development of an automatic analysis of the *P. vivax* transcriptome aimed at identifying parasite genes that have dominant transcription during schizont stages, mainly 30– 48 hours post-infection, based on the rationale that they could be encoding proteins involved in *P. vivax* invasion of human reticulocytes [4].

Hidden Markov models (HMMs) are among the most effective and efficient approaches for analyzing large sets of biological data [6–8]. These models have been applied over the last 20 years in sequence analysis, gene finding and protein family characterization [9]. Chen et al., designed a predictor for secreted proteins using HMM-based methods in 2003 to identify signal peptides and transmembrane proteins [10]; in 2009 Tinhosolo et al., identified carotenoid genes in P. falciparum by comparing biosynthesis-related genes against a local database of P. falciparum genes using BLAST and HMM [11]. In the same year, Gaskell et al., identified secreted enzymes in Toxoplasma gondii using SHARKhunt which used profile HMM based on the PRIAM polypeptide profile library to search for a set of genomic DNA sequences potentially encoding such proteins [12]. In 2010, Arena et al., identified 16 new genes encoding trypsin proteases in 8 Apicomplexan genomes [13]. Ghouila et al., constructed a system for identifying protein domains based on comparing HMM and Pfam profiles so that a Pfam family was represented by a multiple sequence alignment and a profile HMM [14].

More specifically, different HMM-based approaches have been proposed for the search, identification and characterization of new vaccine candidate proteins in the Plasmodium genus. A method for detecting new protein domains in *P. falciparum* using cooccurrence was proposed by Terrapon *et al.*, in 2009 [15]. This method has been claimed to improve the sensitivity of Pfam domain detection. More recently, Bischoff and Vaquero, in 2010 [16], reported a set of proteins potentially involved in the transcriptional machinery of the Plasmodium genus, based on *in silico* reports and databases. Particularly, a directory of factors associated with Plasmodium transcription was built by scanning the Plasmodium genome using profile HMMs. It should be stressed that HMMER software was used for the searches related to both methods [17].

One of the most used profile HMM-based tools is HMMER v3.0 which is a new generation of sequence homology search software that is used for querying sequence databases for protein homologues and performing protein alignment. Compared to BLAST, FASTA and other sequence alignment and database search tools based on classical scoring methodology, HMMER has been shown to be significantly more accurate and better at detecting remote homologues because of the strength of its underlying mathematical models. In the past, this strength came at significant computational expense, but in the new HMMER3 project, HMMER is now essentially as fast as BLAST [18].

Several adjustments to the input data are required as part of the process for obtaining the different probabilistic profile HMMs taking into account that, if there is a high degree of similarity among the biological sequences, any analysis could be biased due to redundancy. Different efficient algorithms allow a set of sequences to be constructed with a degree of similarity below a given parameter. Cd-hit uses an algorithm based on short word filtering (i.e. dipeptides, tripeptides, etc.) to determine protein similarity taking into account the minimum number of identical short substrings [19]. On the other hand, PISCES [20] uses PSI-BLAST and an inclusion/exclusion label process that is based on the size of the parameter that determines the similarity threshold.

This study describes an approach to the large-scale identification and selection of proteins playing an active role in P. vivax invasion of human reticulocytes. It is based on identifying secreted and/or invasion-related proteins using sequence redundancy reduction and profile HMMs to analyze genome-annotated genes with significantly high levels of transcription toward the end of the intra-erythrocyte cycle. The preference for this transcriptional stage was based on the premise that gene expression is timely regulated and therefore biological functions can be assigned to a particular instant of the parasite's developmental cycle inside the infected red blood cell [4]. The selected candidates were further analyzed; this included reviewing published experimental evidence of role during invasion and/or immunological assays leading to their classification as vaccine candidates and experimental confirmation of protein presence. Supporting information based on the prediction of subcellular localization and signal sequence, number of transmembrane regions, identification of glycosylphosphatidylinositol (GPI)-anchor sites and functional domains related to invasion, and prediction of adhesion activity was also assessed. The objective was to define robust selection criteria based on a bioinformatics strategy to find P. vivax proteins likely to be interesting vaccine candidates.

Results

The results were based on the 3 phases proposed in the methodology (Figure 1). The first one consisted of constructing 36 profile HMMs and a target data set of 582 *P. vivax* open reading frames (ORFs) with predominant transcription toward the end of the intra-erythrocyte cycle. In the second phase (identification), the 36 profile HMMs were used for exploring the target data set, leading to the discovery of 46 *P. vivax* ORFs scanned by the profile HMMs. Forty-five of them encoded potentially secreted and/or invasion-related proteins, while the remaining one belonged to the negative set. It is worth noting that ORFs were included irrespective of whether they were identified once or several times. The resulting ORFs/proteins were screened in the third phase according to a literature review of published evidence regarding their secretion or previous use as vaccine candidates.

Phase 1: Constructing protein profile HMMs (1a) and target data set (1b)

Nine protein sequence data sets were also constructed to create the protein profile HMMs. It should be highlighted that data sets had different construction criteria, were processed by 2 different redundancy reduction algorithms and that cut-off values were established at 2 different identity percentages, leading to 36 profiles in total being obtained (Table 1).

Table 2 shows the ORFs/proteins identified by the 36 profile HMMs that were constructed from 9 Plasmodium protein data sets (Table S1); 8 of them were considered as secreted and some have been reported as being involved in invasion, while the remaining set contained the non-secreted proteins.

The target data set was constructed from proteins encoded in the *P. vivax* genome showing a peak transcription at the end of the intra-erythrocyte development cycle and which could therefore have potential roles in the invasion of reticulocytes [4]. Consequently, this data set only included genes exhibiting a Cy5/Cy3 expression ratio larger than 1.5 at the end of the intraerythrocyte cycle (31–48 hours post-invasion) (Table S2).




Figure 1. Methodology for identifying *Plasmodium vivax* proteins having a potential role in invasion using sequence redundancy reduction and profile hidden Markov models. doi:10.1371/journal.pone.0025189.q001

Phase 2: Protein profiles against the target data set and identification step

The analysis shows that, even though some sequences were shared between profile HMMs, the different modifications applied to the 9 protein data sets led to different results being obtained in all cases, except for the negative profile, in which all the 4 profile HMM modifications pointed to the same protein (PVX_090110), as will be further explained below (Table 2).

A close analysis of Table 2 indicates that the 36 profile HMMs allowed tracking new candidate ORFs/proteins. Interestingly, 34 out of the 46 ORFs/proteins identified by the different profile HMMs were identified by more than one profile HMM, while the remaining 12 were identified only once. The most frequently identified ORFs/proteins were: PVX_117880 (27 times), PVX_092975 (18 times) and PVX_002510 (17 times). On the other hand, PVX_080305, PVX_112665, PVX_092995, PVX_081810, PVX_101505, PVX_094425, PVX_086850,

PVX_081845, PVX_097710, PVX_123550, PVX_109280, and PVX_118525 were identified only once. The profile HMMs labeled as "42, Pisces 90% identity", "67, Cd-hit 30% identity", "88, Cd-hit 30% identity" and "118, Pisces 30% identity" in Table 2 were those that identified the largest number of ORFs/ proteins (12 in total).

Regarding the negative set, containing non-secreted reported ORFs/proteins used as a probe to validate the consistency of the results, only PVX_090110 was identified as a non-secreted protein out of the initial set of target proteins. This was the only case in which all profile HMMs identified the same protein.

Table S3 shows the protein domain families indexed in PFAM (version 25.0), which were reported by the hmmscan algorithm as being related to each built data set's protein sequences. Specifically, 310 domains were scanned in the PFAM database. The AMA-1 Apical membrane antigen 1, DUF605 Vta 1 like and MSP7_C MSP7-like protein C-terminal domains were the most

Table 1. Plasmodium protein data sets used for profile HMMs construction.

			Protein exist	ence**			Organism			
# of proteins	Туре	Query	Prot/Trans	Predicted	Putative	Homology	P. falciparum	P. vivax	P. berghei	P. yoelii
129*	Neg	Database	34	1	0	94	75	10	12	12
133	Pos	Database	21	81	22	9	79	28	15	11
118	Pos	Lit/DB	20	69	22	7	66	28	14	10
110	Pos	Database	21	81	0	1	71	21	8	10
88	Pos	Lit/DB	20	69	0	0	54	20	6	8
68	Pos	Lit/DB	0	68	0	0	48	11	4	5
67	Pos	Literature	6	48	8	5	67	0	0	0
42	Pos	Lit/DB	20	0	22	0	12	16	10	4
20	Pos	Lit/DB	20	0	0	0	6	9	2	3

*The remaining protein sequences correspond to P. chabaudi (10), P. knowlesi (8), P. gallinaceum (1) and P. malariae (1).

**Level of evidence that supports the existence of the protein concerned. "Prot/Trans" indicates that there is clear experimental evidence for the existence of the protein or that expression data indicate the existence of a transcript. "Homology" indicates that the existence of a protein is probable because orthologs exist in closely-related species. "Predicted" is used for entries without evidence at protein, transcript, or homology levels. 'Putative' indicates putative proteins having predicted existence.

doi:10.1371/journal.pone.0025189.t001

20 42 42 64<	20 42 42 42 43<		Prote	Protein profile datasets	ïle dat	asets																				
olde olde <th< th=""><th></th><th></th><th>20</th><th></th><th></th><th></th><th>42</th><th></th><th></th><th>67</th><th></th><th></th><th>68</th><th></th><th>88</th><th></th><th></th><th>110</th><th></th><th>118</th><th></th><th>133</th><th></th><th>12</th><th>6</th><th></th></th<>			20				42			67			68		88			110		118		133		12	6	
M M	A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A A <th></th> <th>cd-hi</th> <th>L.</th> <th>pis</th> <th>ces</th> <th>cd-hit</th> <th>,id</th> <th>sces</th> <th>cd-hit</th> <th></th> <th>isces</th> <th>cd-hit</th> <th>pisce</th> <th></th> <th></th> <th>pisces</th> <th>cd-hit</th> <th>pisces</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>isces</th>		cd-hi	L.	pis	ces	cd-hit	,id	sces	cd-hit		isces	cd-hit	pisce			pisces	cd-hit	pisces							isces
x x	x x	ID proteins	ø	٩	a I	٩		a I	q			٩								ø	a,	a				
		PVX_090110																						×		
i i	N N	PVX_117880						×	×											×		×		×		
		PVX_003905																				×	×	×		
1 1 </td <td>x x</td> <td>PVX_092975</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>×</td> <td>×</td> <td></td> <td>×</td> <td></td> <td></td> <td></td> <td>×</td> <td></td> <td>×</td> <td></td> <td></td> <td></td> <td>×</td> <td></td> <td></td> <td>×</td> <td></td> <td></td>	x x	PVX_092975						×	×		×				×		×				×			×		
1 1	1 1	PVX_121920						×	×				×							×	×		×			
1 1	1 1	PVX_003800	×	×	×	×		×	×		×							×	×			^	×	×		
 x x<	i i	PVX_003825	×	×	×	×	×	×	×		×							×	×			^	×			
x x <td>x x<td>VX_121885</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>×</td><td></td><td>×</td><td>×</td><td></td><td>×</td><td></td><td>×</td><td>×</td><td>×</td><td></td><td>Â</td><td>×</td><td></td><td></td><td></td></td>	x x <td>VX_121885</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>×</td> <td></td> <td>×</td> <td>×</td> <td></td> <td>×</td> <td></td> <td>×</td> <td>×</td> <td>×</td> <td></td> <td>Â</td> <td>×</td> <td></td> <td></td> <td></td>	VX_121885									×		×	×		×		×	×	×		Â	×			
 Normal Series Series	X X <td>VX_003805</td> <td>×</td> <td>×</td> <td>×</td> <td>×</td> <td>×</td> <td>×</td> <td>×</td> <td></td> <td>×</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>×</td> <td>×</td> <td></td> <td></td> <td>^</td> <td></td> <td></td> <td></td> <td></td>	VX_003805	×	×	×	×	×	×	×		×							×	×			^				
 x x<	x x	VX_003850	×	×	×	×	×	×	×		×							×	×			Â		×		
x x	Normal Solution Solutica Solutica Solutica Solutica Solutica Solutica Solutica So	VX_002510																			×		×			
Normal Solution of Control of	Normal Solution Solutica Solutica Solutica Solutica Solutica Solutica Solutica So	086660 X/c											×	×		×	×		×	×			×	×		
Normal Solution (1) Normal Solution (1	Normal Solution Solutica Solutica Solutica Solutica Solutica Solutica Solutica So	0767_0_XVc											×	×	×				×	×			×			
x x	Normal Source	VX_097720								×				×	×				×	×	×		×			
Normal Solution Solutica Solutica Solutica Solutica Solutica Solutica Solutica So	x x	089760_XVc																			×		×			
x x	x x	PVX_098585						×	×											×						
X X	X X X X X X X X X X X X X X X X X X X	PVX_097715												×		×	×				×					
X X X X X X X X X X X X X X X X X X X	x x	VX_090210											×							×						
x x x x x x x x x x x x x x x	x x x x x x x x x x x x x	066960 [—] X/c										×	×	×			×									
x x x x x x x x	<pre>x x x x x x x x x x x x x x x x x x x</pre>	207700_XVc								×		×	×				×				×					
x x	x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x <t< td=""><td>VX_084720</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>×</td><td></td><td></td><td></td><td></td><td>×</td><td></td><td></td><td></td><td></td><td>×</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	VX_084720								×					×					×						
x x	x x	PVX_117230															×			×						
 x x<	x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x x <td>PVX_123105</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>×</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>×</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	PVX_123105								×										×						
x x x x x <	x x x x x <	PVX_097700										×		×							×					
 × ×<	 × ×<	PVX_097695									×		×													
 x x<	x x x x x x x x x x x x x x x x x x x	PVX_097710																			×					
x x x x x x x x x x x x x x x x x x x	x x x x x x x x x x x x x x x x x x x	PVX_097675									×	×	×			×					×					
x x x x x x x x x x x x x x x x x x x	x X X X X X X X X X X X X X X X X X X X	PVX_101555														×					×					
x x x x x x x x x x	× × × × × × × ×	PVX_003830	×	×	×	×	×	×	×		×						×	×	×							
		VX_085930	×	×	×	×		×	×										×							

	Protein profile datasets	datasets															
	20		42		67		68		88	110	0	118		133		129	
	cd-hit	pisces	cd-hit	pisces	cd-hit	pisces	cd-hit	pisces	cd-hit p	pisces cd-	cd-hit pisces	s cd-hit	pisces	cd-hit	pisces	cd-hit p	pisces
ID proteins	a d	a b	a b	a b	a b	a b	a b	a b	a b	a b a	p b	a b	a b	a b	a b	a b a	q
PVX_101605					×			×	×	×							
PVX_092995									×								
PVX_123550									×								
PVX_118525									×								
PVX_081810									×	~							
PVX_101505										×							
PVX_109280										×							
PVX_094425							×										
PVX_092425					×			×									
PVX_086850					×												
PVX_081845					×												
PVX_082695			×	×													
PVX_003815	×	×	×	×													
PVX_097590	×	×		×													
PVX_080305	×																
The characters "a' doi:10.1371/journa	The characters "a" and "b" represent 30% and 90% identity thresholds, respectively. doi:10.1371/journal.pone.0025189.t002	t 30% and 90% 12	identity thre	sholds, respectiv	ely.												

MC 1203 S elected Dependent contened Ele Sec Sec Sec MC 13235 F Sected Dyporticic pretri Ele Sec Sec <th>Protein ID</th> <th>E. Ref</th> <th>Category</th> <th>NAME</th> <th>ESLPred2</th> <th>BaCelLo</th> <th>SignalP</th> <th>TM Pphob</th> <th>SP Pphob</th> <th>SecretomeP</th> <th>тмнмм</th> <th>GPI</th> <th>DOM</th> <th>MAAPs</th>	Protein ID	E. Ref	Category	NAME	ESLPred2	BaCelLo	SignalP	TM Pphob	SP Pphob	SecretomeP	тмнмм	GPI	DOM	MAAPs
5Selectedhypothetical protein, conservedEdSelect222315Selectedhypothetical protein, conservedEdSelect111111Selectedhypothetical protein, conservedEdSelect11111111Selectedhypothetical protein, conservedEdSelect111	VX_123105	ı	Selected	hypothetical protein, conserved	Ext	Sec								
·Selectedtypopterical protein, conservedEdSelecttypopterical protein, conservedEdSelect····××	VX_101605	,	Selected	hypothetical protein	Ext	Sec		2		×	2	РЕР		
·SelectedbitsSelectMyorhetical protein, conservedEx·······SelectedMyorhetical protein, conservedExMM·· <td< td=""><td>VX_123550</td><td></td><td>Selected</td><td>hypothetical protein, conserved</td><td>Ext</td><td>Sec</td><td></td><td></td><td></td><td>×</td><td></td><td></td><td></td><td></td></td<>	VX_123550		Selected	hypothetical protein, conserved	Ext	Sec				×				
·Selectedbyotherical protein, conservedbitCit·····Selectedbyotherical protein, conservedExtM11112··Selectedbyotherical protein, conservedExtSe1112··Selectedbyotherical protein, conservedExtSelect1112··SelectedPyotherical proteinExtSelect1112··SelectedPyotherical proteinExtSelect1112··SelectedSelectedSelectedSelected1112··SelectedSelectedSelectedSelected11112··SelectedSelectedSelectedSelected11111··SelectedSelectedSelectedSelected11111··SelectedSelectedSelectedSelected1111111··SelectedSelectedSelectedSelectedSelected11111111111111111111111111111111<	VX_118525	ı	Selected	hypothetical protein, conserved	Ext	Sec	1–18	-	1–20		1			
·Selectedhypothetical protein, conservedEq.Eq.1/271/21/27··Selectedhypothetical protein, conservedEd.Sec.1/27111··Selectedhypothetical protein, conservedEd.Sec.1/27111··Selectedhypothetical protein, conservedEd.Sec.1/27111··Selectedhypothetical proteinEd.Sec.1/27111··SelectedProfined proteinEd.Sec.1/27111··SelectedProfined proteinEd.Sec.1/27111··SelectedProfined proteinEd.Sec.1/27111··SelectedProfined proteinEd.Sec.1/27111··SelectedProfined proteinEd.Sec.1/27111··SelectedProfined proteinEd.Sec.1/261111··SelectedProfined proteinEd.Sec.1/271111··SelectedProfined proteinEd.Sec.1/261111··SelectedProfined proteinEd.Sec.1/261111 <td>VX_081810</td> <td>ı</td> <td>Selected</td> <td>hypothetical protein, conserved</td> <td>Ext</td> <td>Cyt</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	VX_081810	ı	Selected	hypothetical protein, conserved	Ext	Cyt								
.Selectedhypothetical protein, conservedEtcEtc11123.Selectedhypothetical protein, conservedEtcSec3X.Selectedhypothetical protein, conservedEtcSec3X.Selectedhypothetical protein, conservedEtcSec11.Selectedhypothetical protein, conservedEtcSec111.Selectedhymothetical proteinEtcSec121Selectedeythroopte binding proteinEtcSec121Selectedeythroopte binding proteinEtcSec121Selectedeythroopte binding proteinEtcSec121Selectedeythroopte binding proteinEtcSec121Selectedeythroopte binding proteinEtcSec1212Selectedeythroopte binding proteinEtcSec1212Selectedeythroopte binding proteinSelectedSec1212Selectedeythroopte binding proteinSelectedSec2 <t< td=""><td>VX_094425</td><td>ı</td><td>Selected</td><td>hypothetical protein, conserved</td><td>Ext</td><td>Mit</td><td>1–27</td><td>11</td><td>1–27</td><td></td><td>6</td><td></td><td></td><td></td></t<>	VX_094425	ı	Selected	hypothetical protein, conserved	Ext	Mit	1–27	11	1–27		6			
i Selected Nypothetical protein Etc Selected Nypothetical protein X i Selected Nypothetical protein Nypothical protein Nypothetical protein	VX_092425		Selected	hypothetical protein, conserved	Ext	Sec		-	1–23			ЧЬ		
\cdot SelectedNyotherical protein, conservedExt \cdot </td <td>VX_081845</td> <td></td> <td>Selected</td> <td>hypothetical protein</td> <td>Ext</td> <td>Sec</td> <td></td> <td>m</td> <td></td> <td>×</td> <td>2</td> <td></td> <td></td> <td></td>	VX_081845		Selected	hypothetical protein	Ext	Sec		m		×	2			
.Selectedhypothetical poteinExtSelectedhypothetical potein11.SelectedNudeesomal binding poteinKSe1311.SelectedPx/fmx d poteinKKSec1311.SelectedPx/fmx d poteinKKK1111.SelectedPx/fmx d poteinKKK11111.SelectedPx/fmx d poteinKKK12111.SelectedSelectedSelectedSelectedSelected12111.SelectedSelectedSelectedSelectedSelected12111.SelectedSelectedSelectedSelectedSelectedSelected12111.SelectedSelectedSelectedSelectedSelectedSelected12111.SelectedSelectedSelectedSelectedSelectedSelectedSelected1211111.SelectedSelectedSelectedSelectedSelectedSelected1111111111111111111111111	VX_080305		Selected	hypothetical protein, conserved	Ext	Sec	1-22		1–22					
iSelectedNucleosomal binding protein 1, putativeCyrSelectedNucleosomal binding protein 1, putativeCyrSelectedNucleosomal binding proteinIiSelectedSer/Thy protein phosphaase family proteinExNucleosomal binding proteinExI111iSelectedSelectedSer/Thy protein phosphaase family proteinExNucleosomal phosphaase family proteinExNucleosomal phosphaase family proteinExNucleosomal phosphaase family proteinEx1111iSelectedSelectedSelectedSelectedSelectedEx1211iSelectedSelectedSelectedSelectedSelected11111iSelectedSelectedSelectedSelectedSelectedSelected11111iSelectedSelectedSelectedSelectedSelectedSelected111111iSelectedSelectedSelectedSelectedSelectedSelected11	VX_101555	ı	Selected	hypothetical protein	Ext	Sec	1–27	m	1–27		e			
6SelectedPx/amd proteinExtSelectedPx/amd proteinExt1117SelectedPx/amd proteinExtNucExt11117SelectedPx/amd proteinExtNucExt11117SelectedPx/amd proteinExtNucExt11117SelectedPx/amd proteinExtNucExt11117SelectedSelectedSelectedSelected111118SelectedSelectedSelectedSelected111119SelectedSelectedSelectedSelected111111SelectedSelectedSelectedSelected1111111SelectedSelectedSelectedSelectedSelected111111SelectedSelectedSelectedSelectedSelected11111111SelectedSelectedSelectedSelectedSelectedSelected1111111111111111111111111111111111 <td< td=""><td>VX_002510</td><td>ı</td><td>Selected</td><td>Nucleosomal binding protein 1, putative</td><td>Cyt</td><td>Sec</td><td></td><td>-</td><td></td><td></td><td>-</td><td></td><td></td><td>×</td></td<>	VX_002510	ı	Selected	Nucleosomal binding protein 1, putative	Cyt	Sec		-			-			×
iSelected $ex/fnrprotein phosphatase family proteinic<icic<ic<ic<ic<ic<ic<ic<ic<ic<ic<ic<ic<ic<ic<ic<ic<<ic<<ic<<ic<<ic<<ic<<ic<<ic<<ic<<ic<<ic<ic<<ic<<ic<<ic<<ic<<ic<<ic<<ic<<ic<<ic<<ic<<ic<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<ic<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<$	066960_XV	,	Selected	Pv-fam-d protein	Ext	Sec	1–23	1	1–23		2			
iSelectedPvfamd proteinExtNuc2iSelectedentin-repeat antigen (SERA)NucSelect1-31-3iSelectedserin-repeat antigen (SERA)ExtSelect1-261-261-26iSelectedserin-repeat antigen (SERA)ExtSelect1-261-261-26iSelectedserin-repeat antigen (SERA)ExtSelect1-261-261-26iSelectedmeczote surface protein 3 alpha (NSP3a), putativeExt1-261-261-26iSelectedmeczote surface protein Vi35, putativeExt1-261-261-26iSelectedvariable surface protein Vi35, putativeExt1-261-261-26iSelectedtransision-blocking traget antigen Px230, putativeExt1-261-261-26iSelectedtransision-blocking traget antigen Px230, putativeExt1-261-261-26iSelectedtransision-blocking traget antigen Px230, putativeExt1-261-261-26iSelectedtransision-blocking traget antigen Px230, putativeExt1-261-	VX_117230	ı	Selected	Ser/Thr protein phosphatase family protein	Ext	Sec		2	1–21					
iSelectedeythnoore binding potent 1NucSec $i-18$ i $i-18$ i Selectedextine-repeat antigen 4 (SRA)ExtSec $i-26$ $i-26$ $i-26$ i Selectedextine-repeat antigen 4 (SRA)ExtSec $i-26$ $i-26$ $i-26$ i Selectedextine-repeat antigen 2 (SRA)ExtSec $i-26$ $i-26$ $i-26$ i Selectedmerozoite surface protein 3 (MSP3), putativeExtSec $i-26$ $i-26$ $i-26$ i Selectedmerozoite surface protein 3 (MSP3), putativeExtSec $i-26$ $i-26$ $i-26$ i Selectedmerozoite surface protein 3 (MSP3), putativeExt $i-26$ $i-26$ $i-26$ $i-26$ i Selectedmerozoite surface protein 3 (MSP3), putativeExt $i-26$ $i-26$ $i-26$ $i-26$ i Selectedmerozoite surface protein 3 (MSP3), putativeExt $i-26$ $i-26$ $i-26$ $i-26$ i Selectedmerozoite surface protein VIS5, putativeExt $i-26$ $i-26$ $i-26$ $i-26$ i Selectedmerozoite surface protein CMS, putativeExt $i-26$ $i-26$ $i-26$ $i-26$ i Selectedmerozoite surface protein CMS, putativeExt $i-26$ $i-26$ $i-26$ $i-26$ i Selectedmerozoite surface protein CMS, putativeExt $i-26$ $i-26$ $i-26$ $i-26$ i S	VX_101505	ı	Selected	Pv-fam-d protein	Ext	Nuc		2			2			
i.e.Selectedserime-repeat antigen 4 (SENA), putativeExtSec1-261-24i.e.Selectedserime-repeat antigen (SENA), putativeExtSec1-221-9i.e.Selectedserime-repeat antigen (SENA), putativeExtSec1-211-9i.e.Selectedmerozotre surface portein 3 (MSP3), putativeExtSec1-211-16i.e.Selectedmerozotre surface portein 3 (MSP3), putativeExtSec1-201-21i.e.Selectedmerozotre surface portein 3 (MSP3), putativeExtSec1-201-21i.e.Selectedmerozotre surface portein 3 alpha (MSP3a), putativeExt1-261-221-22i.e.Selectedmerozotre surface portein 3 alpha (MSP3a), putativeExt1-261-221-22i.e.Selectedmerozotre surface portein Vir35, putativeExt1-261-221-22i.e.Selected/Ehypothericle protein Vir35, putativeExt1-261-221-22i.e.Selected/Ehypothericle protein Vir35, putativeExt1-261-221-22i.e.Selected/Ehypothericle protein Vir35, putativeExt1-261-221-22i.e.Selected/Ehypothericle antigen (PcAnna)Ext1-241-221-22i.e.Selected/Ehypothericle antigen (PvAnna)Ext1-241-221-22i.e.Selected/Ehypothericle antigen (PvAnna)Ext1-2	VX_092975	ı	Selected	erythrocyte binding protein 1	Nuc	Sec	1–18	-	1–18		-		×	×
.Selectedserice-repeat antigen (SERA), putativeExtSec1-21-19.Selectedserice-repeat antigen 2 (SERA)ExtSec1-211-18.Selectedserice-repeat antigen 2 (SERA)ExtSec1-201-18.Selectedmerozoite surface protein 3 (MSP3), putativeExtSec1-201-21.Selectedmerozoite surface protein 3 (MSP3), putativeExtSec1-201-21.Selectedmerozoite surface protein 3 apma (MSP3), putativeExtSec1-221-22.Selectedwaiable surface protein Vi35, putativeExtSec1-241-22.Selectedserine-repeat antigen (SERA), truncated, putativeExtSec1-241-22.Selectedwaiable surface protein Vi35, putativeExtSec1-241-22.Selected-FEtypotherical protein, conservedExtSec1-241-22.Selected-FEtypotherical protein, conservedExtSec1-231-22.Selected-FEtypotherical protein, typutativeExtSec1-231-23.Selected-FEtypotherical protein, typutativeExtSec1-231-23.Selected-FEtypotherical protein, typutativeExtSec1-231-23.Selected-FEtypotherical protein, typutativeExtSec1-231-23.Selected-FEtypother	VX_003825	,	Selected	serine-repeat antigen 4 (SERA)	Ext	Sec	1–26		1–24				×	
Selectedserific-repeat antigen 2 (SERA)ExtSec $1-21$ $$ Selectedmerozoite surface protein 3 (MSP33) putativeExt $2e$ $1-20$ $1-20$ $$ Selectedmerozoite surface protein 3 (MSP33) putativeExt $2e$ $1-20$ $1-20$ $$ Selectedmerozoite surface protein 3 (MSP33) putativeExt $2e$ $1-20$ $1-20$ $$ Selectedmerozoite surface protein 3 gamma (MSP33) putativeExt $1-20$ $1-20$ $1-20$ $$ Selectedmerozoite surface protein 3 gamma (MSP33) putativeExt $1-20$ $1-20$ $1-20$ $$ Selectedserine-repeat antigen 7 (SERA)Ext $1-20$ $1-20$ $1-20$ $$ Selected Fserine-repeat antigen (SERA) truncated, putativeExt $1-20$ $1-20$ $1-20$ $$ Selected Fserine-repeat antigen (SERA) truncated, putativeExt $1-20$ $1-20$ $1-20$ $$ Selected Ftransision-blocking target antigen (Varia-a)Ext $1-20$ $1-20$ $1-20$ $$ Selected Ftransision-blocking target antigen (Varia-a)Ext $1-20$ $1-20$ $1-20$ $$ Selected Ftransision-blockin conservedExt $1-20$ $1-20$ $1-20$ $$ Selected Ftransision-blockin conservedExt $1-20$ $1-20$ $1-20$ $$ Selected Ftransision-blockin conservedExt $1-20$ $1-20$ $1-20$ <t< td=""><td>VX_003805</td><td></td><td>Selected</td><td>serine-repeat antigen (SERA), putative</td><td>Ext</td><td>Sec</td><td>1–22</td><td></td><td>1–19</td><td></td><td></td><td></td><td>×</td><td></td></t<>	VX_003805		Selected	serine-repeat antigen (SERA), putative	Ext	Sec	1–22		1–19				×	
\cdot Selectedmerozoite surface protein 3 (MSP3), putativeExtSec $1-8$ $1-8$ \cdot Selectedmerozoite surface protein 3 alpha (MSP3a), putativeExt 5 $1-20$ $1-20$ \cdot Selectedmerozoite surface protein 3 alpha (MSP3a), putativeExt 5 $1-20$ $1-20$ \cdot Selectedmerozoite surface protein 3 apma (MSP3a), putativeExt 5 $1-20$ $1-20$ \cdot Selectedseine-repeat antigen 5 (SFRA)Ext 5 $1-20$ $1-20$ \cdot Selectedtransision-blocking target antigen $V(35)$, putativeExt 5 $1-24$ $1-22$ \cdot Selectedtransision-blocking target antigen $V(35)$, putativeExt 5 $1-24$ $1-22$ \cdot Selectedtransision-blocking target antigen $V(35)$, putativeExt 5 $1-24$ $1-22$ \cdot Selectedtransision-blocking target antigen $V(25)$, putativeExt 5 $1-22$ $1-22$ \cdot Selected-FEtransision-blocking target antigen $V(25)$ Ext $1-22$ $1-22$ \cdot Selecte	VX_003850		Selected	serine-repeat antigen 2 (SERA)	Ext	Sec	1–21						×	
\cdot Selectedmerozote surface protein 3 alpha (MSP3a), putativeExt \cdot <	VX_097715	ı	Selected	merozoite surface protein 3 (MSP3), putative	Ext	Sec	1–18		1–18			РЕР		
\cdot Selectedmerozoite surface protein 3 gamma (MSP3g), putativeExt $i=20$ $i=20$ \cdot Selectedserine-repeat antigen 5 (SERA)ExtSet $i=24$ $i=22$ \cdot Selectedvariable surface protein Vir35, putativeExtSet $i=24$ $i=22$ \cdot Selectedserine-repeat antigen (SERA), truncated, putativeExtSet $i=24$ $i=22$ \cdot Selectedtransmission-blocking target antigen Poss30, putativeExtSet $i=24$ $i=22$ \cdot Selected-FEtransmission-blocking target antigen Poss30, putativeExtSet $i=24$ $i=24$ \cdot Selected-FEtypotherrich antigen Poss30, putativeExtSet $i=24$ $i=24$ \cdot Selected-FEtypotherrich antigen (Porfam=3)ExtSet $i=24$ $i=24$ \cdot Selected-FEtypothenrich antigen (Porfam=3)ExtSet $i=24$ $i=22$ \cdot Selected-FEtypothenrich antigen (Porfam=3)ExtSet $i=23$ $i=24$ \cdot Selected-FEtypothenrich antigen (Porfam=3)ExtSet $i=23$ $i=23$ \cdot Selected-FEtypothenrich antigen (Porfam=3) <t< td=""><td>VX_097705</td><td>ı</td><td>Selected</td><td>merozoite surface protein 3 alpha (MSP3a), putative</td><td>Ext</td><td>Sec</td><td>1–20</td><td></td><td>1–21</td><td></td><td></td><td></td><td></td><td></td></t<>	VX_097705	ı	Selected	merozoite surface protein 3 alpha (MSP3a), putative	Ext	Sec	1–20		1–21					
-6 electedserine-repeat antigen 5 (SEA)Ext6 cc1-241-22-8 electedvariable surface protein Vir35, putativeExt8 cc31-23-8 electedserine-repeat antigen (SFRA), truncated, putativeExt6 cc1-241-23-8 electedtransmision-blocking target antigen 9x230, putativeExt6 cc1-241-2358 elected-FEtypotherical protein, conservedExt8 cc1-241-2458 elected-FEtypotherical protein, conservedExt8 cc1-241-2458 elected-FEtypotherical protein, conservedExt8 cc1-241-2258 elected-FEtypotherical protein, conservedExt8 cc1-241-2358 elected-FEtypotherical protein 1, putativeExt8 cc1-231-2358 elected-FEmotorical protein 1, putativeExt8 cc1-231-2358 elected-FEhopthreical protein 7 (MSP7), putativeExt8 cc1-231-2358 elected-FEhopthreical protein 7 (MSP7), putativeExt8 cc1-201-2358 elected-FE	VX_097675		Selected		Ext	Sec	1–20		1–20					×
-Sectedvariable surface protein Vir35, putativeExtSec3-Sectedserine-repeat antigen (SEAA), truncated, putativeExtCyt 3 -Sected-FEserine-repeat antigen (SEAA), truncated, putativeExtCyt 3 5Sected-FEtransmission-blocking target antigen Pvs230, putativeExtSec $1-29$ $1-22$ 5Sected-FEtypotherical protein, conservedExtSec $1-24$ 3 $1-24$ 5Sected-FEtypotherical protein, conservedExtSec $1-22$ $1-23$ 5Sected-FEtypotherical protein, tonservedExtSec $1-23$ $1-23$ 5Sected-FEtypotherical protein, tonservedExtSec $1-23$ $1-23$ 5Sected-FEtypotherical protein 1 , putativeExtSec $1-23$ $1-23$ 5Sected-FEthoptry-associated protein 1 , putativeExtSec $1-23$ $1-23$ <td>VX_003830</td> <td>,</td> <td>Selected</td> <td>serine-repeat antigen 5 (SERA)</td> <td>Ext</td> <td>Sec</td> <td>1–24</td> <td></td> <td>1–22</td> <td></td> <td></td> <td></td> <td>×</td> <td></td>	VX_003830	,	Selected	serine-repeat antigen 5 (SERA)	Ext	Sec	1–24		1–22				×	
\cdot Selectederrin-repeat antigen (SFRA), truncated, putativeExt Cyt x \cdot Selectedtransmission-locking target antigen Pvs230, putativeExtSec $1-22$ $1-22$ 5 Selected-FEtypotheric linked asexual protein, CLAG, putativeExtSec $1-24$ $1-22$ 5 Selected-FEtypotheric nonservedExtSec $1-22$ $1-22$ 5 Selected-FEtypothen-rich antigen (Pv-fam-a)ExtSec $1-22$ $1-23$ 5 Selected-FEtypothen-rich antigen (Pv-fam-a)ExtSec $1-22$ $1-23$ 5 Selected-FEtypothen-rich antigen (Pv-fam-a)ExtSec $1-23$ $1-23$ 5 Selected-FEtypothen-rich antigen (Pv-fam-a)ExtSec $1-23$ $1-23$ 5 Selected-FEtypothen-rich antigen (Pv-fam-a)ExtSec $1-23$ $1-23$ 5 Selected-FEthopthan-rich antigen (Pv-fam-a)ExtSec $1-23$ <td>VX_086850</td> <td>ı</td> <td>Selected</td> <td>variable surface protein Vir35, putative</td> <td>Ext</td> <td>Sec</td> <td></td> <td>e</td> <td></td> <td></td> <td>e</td> <td></td> <td></td> <td></td>	VX_086850	ı	Selected	variable surface protein Vir35, putative	Ext	Sec		e			e			
·Selectedtransmission-blocking target antigen Pvs230, putativeExtSec1-291-225Selected-PEcytoadherence linked asexual protein, CLAG, putativeExtSec1-2431-245Selected-PEhypothetical protein, conservedExtSec1-231-225Selected-PEtryptophan-rich antigen (Pv-fam-a)ExtSec1-231-235,32Selected-PEtryptophan-rich antigen (Pv-fam-a)ExtSec1-281-285,32Selected-PEmerozoited protein 1, putativeExtSec1-281-2831Selected-PEhypothetical protein 7 (MSP7), putativeExtSec1-201-2832Selected-PEhypothetical protein 7 (MSP7), putativeExtSec1-291-2833Selected-PEhypothetical protein, conservedExtSec1-201-2834Selected-PEhypothetical protein, conservedExtSec1-291-2835VC-AAmerozoite surface protein 7 (MSP2), putativeExtSec1-201-2236Selected-PEhypothetical protein, conservedExtSec1-201-2237Selected-PEhypothetical protein, conservedExtSec1-201-2238VC-FAnerozoite surface protein 7 (MSP2), putativeExtSec1-201-2239Selected-PEhypothetical protein, conservedExtSec1-201-22 <tr< td=""><td>VX_003815</td><td>,</td><td>Selected</td><td>serine-repeat antigen (SERA), truncated, putative</td><td>Ext</td><td>Cyt</td><td></td><td></td><td></td><td>×</td><td></td><td></td><td></td><td></td></tr<>	VX_003815	,	Selected	serine-repeat antigen (SERA), truncated, putative	Ext	Cyt				×				
5Selected-FECytoadherence linked asexual protein, CLAG, putativeExtSec1-2431-245Selected-FEhypothetical protein, consevedExtSec1-231-235Selected-FEtryptophan-rich antigen (Pv-fam-a)ExtSec1-231-235,32Selected-FEtryptophan-rich antigen (Pv-fam-a)ExtSec1-281-285,33Selected-FEhoptry-associated protein 1, putativeExtSec1-281-2831Selected-FEhoptry-associated protein 7 (MSP7), putativeExtSec1-201-2230Selected-FEhypothetical protein, conservedExtSec1-201-2231Selected-FEhypothetical protein, conservedExtSec1-201-2232VC-AAmerozoite surface protein 3 gamma (MSP3g), putativeExtSec1-1731-1723VC-FAmerozoite surface protein 2 (RBP2), likeExtSec1-211-2224VC-FAmerozoite surface protein 2 (RBP2), likeExtSec1-1731-1725VC-FAmerozoite surface protein 2 (RBP2), likeExtSec1-211-2126VC-FAmerozoite surface protein 2 (RBP2), likeExtSec1-211-2127VC-FAmerozoite surface protein 2 (RBP2), likeExtSec1-211-2128VC-FAmerozoite surface protein 2 (RBP2), likeExt1-211-21 </td <td>VX_003905</td> <td>1</td> <td>Selected</td> <td></td> <td>Ext</td> <td>Sec</td> <td>1–29</td> <td></td> <td>1–22</td> <td></td> <td></td> <td></td> <td>×</td> <td></td>	VX_003905	1	Selected		Ext	Sec	1–29		1–22				×	
5Selected-FEhypothetical protein, conservedExtSec1-221-225Selected-FEtryptophan-rich antigen (Pv-fam-a)ExtSec1-231-235,32Selected-FEtryptophan-rich antigen (Pv-fam-a)ExtSec1-281-285,32Selected-FEhoptry-associated protein 1, putativeExtSec1-281-2831Selected-FEhoptry-associated protein 7 (MSP7), putativeExtSec1-221-2230Selected-FEhypothetical protein, conservedExtSec1-201-2222VC-AAmerozoite surface protein 3 gamma (MSP3), putativeExtSec1-1731-1728VC-FAreticuloryte-binding protein 2 (RBP2), likeExtSec1-201-20	VX_121885	5	Selected-PE	cytoadherence linked asexual protein, CLAG, putative	Ext	Sec	1–24	e	1–24		1		×	
5Selected-FEtryptophan-rich antigen (Pv-fam-a)ExtSec1-231-235Selected-FEtryptophan-rich antigen (Pv-fam-a)ExtSec1-281-285,32Selected-FEhoptry-associated protein 1, putativeExtSec1-221-2831Selected-FEmerozoite surface protein 7 (MSP7), putativeExtSec1-221-2230Selected-FEhypothetical protein, conservedExtSec1-201-2222VC-AAmerozoite surface protein 3 gamma (MSP3), putativeExtSec1-1731-1728VC-FAreticuloxte-binding protein 2 (RBP2), likeExtSec1-201-20	VX_084720	5	Selected-PE	hypothetical protein, conserved	Ext	Sec	1–22		1–22					×
5Selected-FEtryptophan-rich antigen (Pv-fam-a)ExtSec1–281–285,32Selected-PErhoptry-associated protein 1, putativeExtSec1–221–2231Selected-PEmerozoite surface protein 7 (MSP7), putativeExtSec1–201–2230Selected-PEhypothetical protein, conservedExtSec1–1731–1722VC-AAmerozoite surface protein 3 gamma (MSP3g), putativeExtSec1–201–2028VC-FAreticulocyte-binding protein 2 (RBP2), likeExtSec1–201–20	VX_092995	5	Selected-PE	tryptophan-rich antigen (Pv-fam-a)	Ext	Sec	1–23		1–23					
5,32Selected-PErhoptry-associated protein 1, putativeExtSec1–221–2231Selected-PEmerozoite surface protein 7 (MSP7), putativeExtSec1–201–2230Selected-PEhypothetical protein, conservedExtSec1–1731–1722VC-AAmerozoite surface protein 3 gamma (MSP3g), putativeExtSec1–201–2028VC-FAreticulocyte-binding protein 2 (RBP2), likeExtSec1–201–20	VX_112665	5	Selected-PE	tryptophan-rich antigen (Pv-fam-a)	Ext	Sec	1–28		1–28					
31 Selected-PE merozoite surface protein 7 (MSP7), putative Ext Sec 1–20 1–22 30 Selected-PE hypothetical protein, conserved Ext Sec 1–17 3 1–17 22 VC-AA merozoite surface protein 3 gamma (MSP3g), putative Ext Sec 1–20 1–20 28 VC-FA reticulocyte-binding protein 2 (RBP2), like Ext Sec 1–20 1–20	VX_085930	5,32	Selected-PE	rhoptry-associated protein 1, putative	Ext	Sec	1–22		1–22				×	
30 Selected-PE hypothetical protein, conserved Ext Sec 1–17 3 1–17 22 VC-AA merozoite surface protein 3 gamma (MSP3g), putative Ext Sec 1–20 1–20 28 VC-FA reticulocyte-binding protein 2 (RBP2), like Ext Sec 1–21 1 1–21	VX_082695	31	Selected-PE	merozoite surface protein 7 (MSP7), putative	Ext	Sec	1–20		1–22					
22 VC-AA merozoite surface protein 3 gamma (MSP3g), putative Ext Sec 1–20 28 VC-FA reticulocyte-binding protein 2 (RBP2), like Ext Sec 1–21 1	VX_117880	30	Selected-PE	hypothetical protein, conserved	Ext	Sec	1-17	ю	1-17		-			
28 VC-FA reticulocyte-binding protein 2 (RBP2), like Ext Sec 1–21 1	VX_097670	22	VC-AA		Ext	Sec	1-20		1–20					×
	VX_121920	28	VC-FA		Ext	Sec	1–21	-	1–21					

							TM SP					
Protein ID	E. Ref	Category	NAME	ESLPred2 BaCelLo	BaCelLo	SignalP	Pphob Pphol	SignalP Pphob Pphob SecretomeP TMHMM	TMHMM	GPI	DOM	MAAPs
PVX_097590	26	VC-PIA	rhoptry-associated protein 2, putative	Ext	Sec	1–21	1–21					
PVX_109280	24	VC-AA	tryptophan-rich antigen (Pv-fam-a)	Ext	Sec	1–25	1–22					
PVX_090210	10	VC-AA	hypothetical protein	Ext	Sec	1–20	1–20			PFP		
PVX_099980	5,10,27	VC-PIA	major blood-stage surface antigen Pv200	Ext	Sec	1–19	1 1–19		-	НР	×	×
PVX_097680	10	VC-AA	merozoite surface protein 3 beta (MSP3b)	Ext	Sec	1–19	1–19					×
PVX_097700	10	VC-AA	merozoite surface protein 3 (MSP3), putative	Ext	Cyt							×
PVX_097695	10	VC-AA	merozoite surface protein 3 alpha (MSP3a), putative	Ext	Sec	1–20	1–21					
PVX_097710	10	VC-AA	merozoite surface protein 3 (MSP3), putative	Ext	Cyt							×
PVX_003800	25	VC-AA	serine-repeat antigen (SERA)	Ext	Sec	1–25	1–20				×	
PVX_097720	23	VC-AA	merozoite surface protein 3 alpha (MSP3a)	Ext	Mit	1–23	1–23					×
PVX_098585	28,29	VC-FA	reticulocyte-binding protein 1 (RBP1), putative	Ext	Cyt	1–22	1 1–21					
PVX_090110	5	Negative-PE	hypothetical protein, conserved	Ext	Cyt		3					
Abbreviations: E. Ref. refers to the put evidence of protein expression. PIA: Pl pathway. Cyt = cytoplasm, Mit = mitoch doi:10.1371/journal.pone.0025189.t003	. Ref. refers tc ein expression ytoplasm, Mit aal.pone.0025	o the published re n. PIA: Previous p = mitochondrion, 189.t003	Abbreviations: E. Ref. refers to the published reference where the relevant experimental data have been published for each protein. VC: Protein classified as Vaccine Candidate according to previous studies. PE: Experimental evidence of protein expression. PIA: Previous protein on assays. AA: Previous antigenicity assays. FA: Previous functional assays. ESLPred2 (Ext = extracellular, Cys = cytoplasm, Nuc = nuclear), BaCelLo (Sec = secretory pathway, Cyt = cytoplasm, Mit = mitochondrion, Nuc = nuclear), BaCelLo (Sec = secretory doi:10.1371/journal.pone.0025189.t003	ublished for ∈ . FA: Previous alse positive),	each protein. functional as DOM = doma	VC: Protein says. ESLPre ins.	classified as Vaco d2 (Ext = extrace	cine Candidate ac Ilular, Cys = cytop	cording to p lasm, Nuc = r	irevious stu nuclear), Ba	idies. PE: Ex CelLo (Sec:	perimental = secretory

retrieved domains (32 profile HMMs), while the HMM 129 (Cd-Hit 90%) profile scanned the highest number of domains (171 domains in total) (Table S3).

It should be stressed that the negative profile HMM scanned 164 domains that were not recognized by the positive profiles; 139 domains were thus recognized by the positive profiles but not by the negative ones. There were only 7 domains, which were recognized by both positive and negative profile HMMs (Table S3).

Phase 3: Selection step

The 46 proteins identified in the target data set (45 positive and 1 negative) were compared against those reported in the literature and analyzed in terms of several structural features such as the presence of putative classical and non-classical signal sequences, the number of transmembrane helices, the presence of GPIanchor sites, as well as the presence of protein domains relevant for invasion of erythrocytes and able to mediate cell adhesion (Table 3). The final categorization included 13 proteins which had already been classified as vaccine candidates according to previous studies; 9 of these have been tested for their antigenicity [21-25], two have been assayed for their protection-inducing ability [5,21,26,27] and strong reticulocyte-binding ability has been described for the remaining two [28,29]. Experimental evidence of protein expression has been published for 7 additional ORFs; however, no immunological or functional assays testing their potential role as vaccine candidates have been reported yet [5,30-32]. Interestingly, 25 ORFs for which there is no additional experimental evidence, apart from their transcriptional profile, were also identified. This last group plus that containing the seven proteins for which immunological studies are lacking thus became interesting protein candidates to be further tested in vaccination assays (giving a total of 32 selected). The last protein out of the 46 classified was the negative one (Table 3).

Importantly, 18 out of the 32 selected proteins were predicted as being secreted via the classical pathway to the extracellular medium and having a signal peptide, while three additional ones' secretion seems to occur via the non-classical pathway, according to at least four prediction tools. Predictors yielded contradictory results for the 11 remaining proteins.

Discussion

Adjusting and modifying the algorithm parameters shifted the probability of the appearance of biological variables represented in the sequences, thereby broadening the identification of molecules likely to be far-relatives within the target protein data set. It should be noted that, although the data used for constructing the protein profile HMMs were similar (Table 1), the results obtained differed for all profiles so constructed (Tables 2 and 3).

Probabilistically, when a data set is analyzed by means of a redundancy adjustment algorithm, then it would be assumed that, depending on the extent of decreased identity percentage values, there should be more diversity among results. Different identity percentage parameters were thus explored, seeking to favor sequences which, while being different, did share some degree of similarity. The methodology followed in protein set definition and adjustment was thus designed considering that profiles adjusted to 30% identity would be more diverse in terms of the variables included in them. However, since the data sets for constructing the profile HMMs were so limited according to the selection criteria, it was difficult to establish such relationship.

As for the set of the 45 proteins identified, the presence of several of them was somehow expected considering that they belong to families that have already been characterized as good malaria antigen candidates; specifically, 6 proteins belonged to the serine repeat antigen family (SERA) which is considered a vaccine candidate antigen for P. falciparum malaria due to the immunogenicity conferred in rats by one of them when expressed as a recombinant protein [33]. It is worth noting that all 6 proteins identified as being SERA were P. falciparum SERA1, SERA2, SERA3, SERA4, SERA5, SERA6, SERA7 and SERA9 orthologs (Table S4). This group also included two ORFs identified as being rhoptry-associated proteins (RAP1 and RAP2). Some of the previously identified and characterized rhoptry proteins have been found to be actively involved in red blood cell invasion as they are able to bind to red blood cells or since monoclonal or polyclonal antibodies raised against them have inhibited in vitro invasion of target cells [32,34]. An additional rhoptry protein (RON2) [30] expressed in the rhoptry necks was also identified. Previous studies have shown that the RON2 ortholog in P. falciparum is essential for parasite invasion due to its interaction with AMA-1 [35].

The profile HMMs also identified reticulocyte binding proteins (RBP1 and RBP2) which are directly associated with *P. vivax* merozoites' preference for invading human reticulocytes [28]; 9 MSP3 and 1 MSP7 (merozoite surface proteins 3 and 7, respectively) were similarly identified. MSPs are among the best candidate antigens for inclusion in an antimalarial vaccine, mainly because their surface localization facilitates their initial attachment to the red blood cell and involvement in subsequent invasion [36]. Moreover, this localization leaves them accessible to interact with host antibodies.

Regarding the protein identified as negative, it should be noted that it was only identified by the four probabilistic profiles constructed from the data set of 129 proteins, using the redundancy reduction algorithms at 30% and 90% identity (Table 2).

Of the 32 "selected" proteins (Table 3), 26 have orthologs in other species from the Plasmodium genus but the present analysis focused on 21 of them having orthologs in *P. falciparum*. The list of orthologous proteins can be found in Table S4.

Although tools predicting protein localization within a broader range of cellular organelles in eukaryotes are currently available, it has been particularly difficult to define which motifs or domains are exclusively associated with proteins located in apical organelles [37]. The only consensus regarding signals targeting proteins to cell surface or to apical compartments so far consists of the presence of a classical signal sequence or, eventually, the presence of some secondary targeting signals [38,39]. This led us to perform an additional analysis of the set of 45 identified proteins to define priorities in identifying new antigens which are potentially involved in *P. vivax* invasion of reticulocytes. It was thus ascertained whether proteins had a classical signal peptide sequence, as well as the presence and number of transmembrane regions, GPI-anchor sites and domains known to be involved in host-cell invasion, and their ability to mediate cell adhesion.

It has been observed that parasite antigens involved in host-cell invasion that are targeted to membrane or apical organelles are stabilized within such organelles via transmembrane helices or, if such regions are lacking, then by their non-covalent association with other anchored-proteins [39].

It is clear that an important number of *P. falciparum* cell surfaceassociated proteins are attached to the plasma membrane via GPI anchors [40]. Is also well known that some of these proteins play an active role in host-cell invasion through their incorporation into lipid rafts [41], also being recognized by neutralizing antibodies induced during natural malarial infection in people living in endemic areas [42]. Based on these data, various GPI-anchored proteins, such as MSP1 and MSP2, have been or are currently being assessed as candidates for a vaccine against this parasite species [43]. Given the importance of proteins containing GPIanchor sites, understood as a post-translational modification, a GPI-anchored prediction was thus run on the set of 45 proteins identified using the FragAnchor tool [44]. Such analysis predicted a highly probable (HP) GPI-anchor attachment site in 2 of these proteins and 3 had a potentially false positive GPI-anchor site (Table 3).

Despite the difficulty in determining consensus domains and motifs of apical organelle proteins in members of the phylum Apicomplexa, the 45 proteins selected in the computational protein identification were screened against the CODD database [15]. Among the domains used as search query, only those potentially involved in host-cell invasion by mediating adhesion to receptors on the target cell surface or actively involved in shedding-off other parasite proteins were included. This search for *P. vivax* proteins containing one or more of these domains was carried out using PlasmoDB v6.1 based on a list of accession codes for the domains reported in PFAM [45] and InterPro [46] (Table 3).

Another alternative was to check which selected proteins were predicted to act as adhesins. The MAAP [47] tool was thus used which was designed on the sequence composition of a group of proteins from the genus Plasmodium, experimental evidence having shown them to be directly involved in adhesion to host cells (Table 3).

It should be noted that even though the performance of the approach chosen here depended on the current status of parasite genome annotation, the exploratory methodology focused on identifying true positive values and therefore sought to optimize search precision rate. The results are thus not to be measured by the number of proteins so identified but rather by the method's reliability in confirming that such identified proteins are actually true positives. In other words, the fraction of true vaccine candidates among those that the algorithm identified as belonging to the candidates subset had to be close to one.

The information made available through the publication of the genome sequences of several parasites and their hosts, as well as of malaria vector mosquitoes, together with analyses focused on the detection and quantification of parasite gene transcription and protein expression, is now allowing novel strategies to be postulated and better approaches to be adopted for designing more effective vaccines, drugs, diagnostic methods and treatments [48]. This study constitutes an exploratory and rational approach toward the identification of P. vivax proteins playing a potential role in invasion of human reticulocytes based on the search for farhomologues by applying algorithmic techniques for adjusting sequences in regards to redundancy, construct profiles based on HMMs and analyzing protein features such as amino acid composition and secretion pathways.

Materials and Methods

The bioinformatics approach proposed in this paper explored a methodology for identifying *P. vivax* proteins that could be involved in parasite invasion of reticulocytes, therefore making them interesting vaccine candidates. The methodology was based primarily on the use of techniques for reducing sequence redundancy and constructing HMM-based profiles. The main purpose of the methodology was the construction of various probabilistic profiles to search for biologically-related proteins in the *P. vivax* intra-erythrocyte transcriptome. The probabilistic profiles were built using different data sets with sequences from the Plasmodium genus (9 sets in total (Table S1), each with 4 profiles, for

a total of 36 profile HMMs) generated by varying protein feature parameters, and which were adjusted using 2 different methods to reduce redundancies. Proteins identified as possible candidates were further analyzed according to their sequence and additional features to select the most likely vaccine candidates (Figure 1).

The approach followed in this study can be divided into 3 main phases (Figure 1). The objective of the first two phases was to identify proteins potentially involved in *P. vivax* invasion of reticulocytes. These stages involved generating suitable data sets (phase 1a), eliminating protein sequence redundancy (phase 1a), generating protein alignments and obtaining probabilistic profiles based on HMMs (phase 1a), generating the 582 *P. vivax* target data set (phase 1b) (Table S2) and scanning the target data set with the profile HMMs (phase 2). The protein set obtained after these stages included previously reported proteins that had been described as participating in *P. vivax* invasion but, more interestingly, it also contained proteins that have not been previously implicated in cell invasion.

The third phase, denoted as the selection step, consisted of debugging the data set obtained in the previous stages to select the most likely vaccine candidates. This included reviewing scientific literature in the search for previous experimental evidence regarding vaccine candidates or expressed proteins. In addition, the identified proteins were analyzed using different computational classifiers to detect cellular secretion, signal peptides, transmembrane regions, GPI-anchor regions, invasion-related domains and adhesion-like proteins. The orthologs for all the proteins identified are reported in Table S4. A detailed description of each step followed in these 3 phases is given below.

Phase 1: Constructing protein profile HMMs and the target data set

Constructing the protein sequences. Positive and negative sets of proteins were created based on a literature review and search in biological databases (Table 1). In the case of the positive data set, 8 subsets of non-exclusive proteins were formed to model the possible values for a protein's attributes and the organism to which it belonged. Specifically, the attribute "Protein existence" from the SwissProt database was modeled by generating data sets representing each possible value for that attribute ("predicted" and "putative or hypothetical"). Similarly, the organism to which the protein belonged was modeled by including the four species of *Plasmodium* considered here. The negative set consisted of proteins having an annotation of being localized in cytoplasm, nucleus, mitochondria, or retained in the endoplasmic reticulum, whereas the positive set clustered proteins targeted at *P. falciparum, P. vivax, P. berghei* and *P. yoelii* cell surface, rhoptries or micronemes.

Table S1 shows the 9 different data sets created for the exploration. It should be noted that there was no exclusive set of proteins for each data set, but rather proteins were shared between more than one set.

The set construction generated sets having divergent features (Table 1). Specifically, the number of sequences ranged between 133 sequences (Set 2) and 20 sequences (Set 9). Some of the sets resulted from combining searches in databases and literature reviews (Sets 3 and 5 to 9) while other sets were built strictly on query results from databases (Sets 1, 2 and 4). The parameter of "existence" diverged between the sets, allowing for some of them to contain proteins for all possible values (Sets 2, 3 and 7) whereas others were restricted to proteins combining two of these annotations (Sets of 4, 5 and 8) and others were restricted to proteins with one particular type of annotation (Set 6 and 9). Regarding distribution in the organism of origin, some sets were

unbalanced in favour of *P. falciparum* (Sets 1 to 7) while others tended to cluster proteins from *P. vivax* (Sets 8 and 9).

It is worth noting special features for certain data sets. For example, Set 7 clustered 67 *P. falciparum* proteins reported as being involved in invasion and with annotations of function, subcellular localization and time during the cycle in which they are transcribed [49]. Similarly, all proteins present in the data sets were compared with the target set and were extracted before constructing the profiles. This step was carried out to avoid biasing profile construction by favoring sequences repeated between a specific profile and the target set.

An essential premise was that the divergence among the data sets reported in Table 1 allowed generating different probabilistic profiles, therefore leading to different search approaches within the target data set. The negative set was used to validate the robustness of the results obtained in the exploration of the target data set.

Reducing redundancy. The task was performed by applying the Cd-hit [19] and PISCES [20] algorithms to each of the 9 protein profile data sets (defined in the previous subsection), according to 2 identity parameters (30% and 90% identity). This reduction of redundancy resulted in a total of 36 subsets.

Constructing protein profile HMMs data sets. This stage consisted of obtaining protein alignments. Sequence alignments for the 36 subsets (defined in the previous subsection) were obtained using the ClustalW2 suite [50].

A profile HMMs comparison between the different data sets and the PFAM 25.0 database was also performed. Specifically, the 'hmmscan' algorithm in the HMMER v3.0 suite [18] was the choice selected for a protein sequence vs profile-HMM database query. Table S3 shows the domains reported as being related to data set protein sequences. The profile HMMs are publicly available in http://www.biolisi.unal.edu.co/publications/supplementary-files/p_ vivax/.

Target data set. This set was constructed on *P. vivax* gene mRNA abundance levels during each time interval during the intra-erythrocyte cycle, expressed in terms of the degree of RNA hybridization in the microarray compared to hybridization in the RNA reference pool assembled from the RNA samples from all time points for the 3 studied isolates [4]. Of the total of 5,335 genes analyzed in the 3 clinical isolates, only those genes showing a Cy5/Cy3 ratio higher than 1.5 in the TP7–9 time interval (corresponding to 31–48 hours of intra-erythrocyte cycle), but not in any of the previous time intervals (TP1–6), were selected. This selection considered genes that did not have a single maximum transcription peak at the end of the intra-erythrocyte cycle.

It should be noted that genes having larger transcription peaks at any previous time (0-30 hours) were not taken into account. The transcription criteria "at the end of the intra-erythrocyte cycle" was chosen due to previous evidence showing that most *P. falciparum* genes encoding proteins having important roles in erythrocyte invasion have a peak transcription during this lapse of time, which agrees with merozoite maturation and the development of apical organelles (rhoptries, micronemes and dense granules) [51]. This resulted in a target data set of 582 transcribed genes (Table S2).

All amino acid sequences used in this study, either identified previously or as a result of *P. falciparum* and *P. vivax* genome annotation were downloaded from the PlasmoDB database [52], with their corresponding accession codes.

Phase 2: Protein profiles against target data set and protein identification

The probabilistic profiles were obtained and used as query for searching in the target protein data set using HMMER v 3.0 software [18]. The results for this phase are reported in Table 2.

Phase 3: Protein selection

The protein identification described in the previous section defined a set of 46 candidates (Table 3). This set of proteins was further characterized according to structural features regarding secretion and the transcriptional profile reported in PlasmoDB. These results were then contrasted with previous literature reports to classify proteins already being considered as vaccine candidates and those that were not. As a result of this analysis, the identified proteins were grouped into two categories: "vaccine candidates" and "selected". The respective sub-categories can be found in Table 3.

The *P. vivax* gene homologues located in syntenic regions were identified in the annotated *P. falciparum* genome by screening the PlasmoDB [52] and the OrthoMCL–DB [48] databases (Table S4). The subcellular localization of the pool of proteins selected based on the abovementioned criteria was also predicted using tools based on Support Vector Machine (SVM) systems and/or homology-based analyses. The ESLpred2 tool [53] hosted at http://www.imtech.res.in/raghava/eslpred2/ and BaCelLo [54] available at http://gpcr.biocomp.unibo.it/ bacello/were used, selecting the animal kingdom-specific predictor in both cases.

The next step was to screen proteins for the presence of a signal peptide using various tools for predicting the secretion pathway in eukaryotic proteins. SignalP 3.0 [55] http://www.cbs.dtu.dk/ services/SignalP/was used for classical secretion as it combines neural networks (NN) and hidden Markov models (HMM), as well as PolyPhobius [56] http://phobius.sbc.su.se/poly.html, a tool that allows determining transmembrane topology performing an HMM algorithm using homology information. Secretion via non-classical pathways was predicted using SecretomeP 2.0 [57] available at http://www.cbs.dtu.dk/services/SecretomeP/.

Transmembrane helices and GPI anchors were also reported as part of the analysis. PolyPhobius and TMHMM v 2.0 [58] http:// www.cbs.dtu.dk/services/TMHMM/were used for predicting the presence and number of transmembrane regions in the pool of chosen peptide sequences. The latter tool is based on the use of an HMM; however, unlike PolyPhobius, TMHMM sometimes incorrectly classifies the signal peptide as a transmembrane region. Those regions predicted as transmembrane helices but showing at least 50% similarity with one or both of the signal peptide predictions mentioned above were thus discarded. All proteins were analyzed for the presence of GPI-anchor sites using FragAnchor (http://navet.ics.hawaii.edu/~fraganchor/NNHMM/ NNHMM.html) [44] which is based on the tandem use of NN and HMM predictors.

P. vivax proteins having a potential adhesive function, being understood as a protein's ability to adhere to another protein or molecule on red blood cell surface, were identified using the Malarial Adhesins and Adhesin–like proteins (MAAP) predictor [59] available at http://maap.igib.res.in/, which is a nonhomology-based approach that implements the compositional characteristics of amino acid dipeptides and multiplet frequencies with an SVM-based classification system.

Supporting Information

Table S1 Profile data sets. $\rm (XLS)$

Table S2Target data set.(XLS)

Table S3 Pfam domains related to the data sets constructed.

(XLS)

Table S4 Ortologs of the identified proteins found in other Plasmodium species. (XLS)

References

- Lopez AD, Mathers CD (2006) Measuring the global burden of disease and epidemiological transitions: 2002–2030. Ann Trop Med Parasitol 100: 481–499.
 Feachem RG, Phillips AA, Hwang J, Cotter C, Wielgosz B, et al. (2010)
- Shrinking the malaria map: progress and prospects. Lancet 376: 1566–1578.
 3. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, et al. (2008) Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 455: 757–763.
- Bozdech Z, Mok S, Hu G, Imwong M, Jaidee A, et al. (2008) The transcriptome of Plasmodium vivax reveals divergence and diversity of transcriptional regulation in malaria parasites. Proc Natl Acad Sci U S A 105: 16290–16295.
- Roobsoong W, Roytrakul S, Sattabongkot J, Li J, Udomsangpetch R, et al. (2011) Determination of the Plasmodium vivax schizont stage proteome. J Proteomics.
- Krogh A, Brown M, Mian IS, Sjolander K, Haussler D (1994) Hidden Markov models in computational biology. Applications to protein modeling. J Mol Biol 235: 1501–1531.
- Karplus K, Barrett C, Hughey R (1998) Hidden Markov models for detecting remote protein homologies. Bioinformatics 14: 846–856.
- Gough J, Karplus K, Hughey R, Chothia C (2001) Assignment of homology to genome sequences using a library of hidden Markov models that represent all proteins of known structure. J Mol Biol 313: 903–919.
- De Fonzo V, Aluffi-Pentini F, Parisi V (2007) Hidden Markov models in bioinformatics. Current Bioinformatics 2: 49–61.
- Chen Y, Yu P, Luo J, Jiang Y (2003) Secreted protein prediction system combining CJ-SPHMM, TMHMM, and PSORT. Mamm Genome 14: 859–865.
- Tonhosolo R, D'Alexandri FL, de Rosso VV, Gazarini ML, Matsumura MY, et al. (2009) Carotenoid biosynthesis in intraerythrocytic stages of Plasmodium falciparum. J Biol Chem 284: 9974–9985.
- Gaskell EA, Smith JE, Pinney JW, Westhead DR, McConkey GA (2009) A unique dual activity amino acid hydroxylase in Toxoplasma gondii. PLoS One 4: e4801.
- Arenas AF, Osorio-Mendez JF, Gutierrez AJ, Gomez-Marin JE (2010) Genomewide survey and evolutionary analysis of trypsin proteases in apicomplexan parasites. Genomics Proteomics Bioinformatics 8: 103–112.
- Ghouila A, Terrapon N, Gascuel O, Guerfali FZ, Laouini D, et al. (2010) EuPathDomains: The divergent domain database for eukaryotic pathogens. Infect Genet Evol 11: 698–707.
- Terrapon N, Gascuel O, Marechal E, Breehelin L (2009) Detection of new protein domains using co-occurrence: application to Plasmodium falciparum. Bioinformatics 25: 3077–3083.
- Bischoff E, Vaquero C (2010) In silico and biological survey of transcriptionassociated proteins implicated in the transcriptional machinery during the erythrocytic development of Plasmodium falciparum. BMC Genomics 11: 34.
- 17. Eddy SR (1998) Profile hidden Markov models. Bioinformatics 14: 755-763.
- Eddy SR (2009) A new generation of homology search tools based on probabilistic inference. Genome Inform 23: 205–211.
- Li W, Godzik A (2006) Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences. Bioinformatics 22: 1658–1659.
- Wang G, Dunbrack RL, Jr. (2003) PISCES: a protein sequence culling server. Bioinformatics 19: 1589–1591.
- Chen JH, Jung JW, Wang Y, Ha KS, Lu F, et al. (2010) Immunoproteomics profiling of blood stage Plasmodium vivax infection by high-throughput screening assays. J Proteome Res 9: 6479–6489.
- Galinski MR, İngravallo P, Corredor-Medina C, Al-Khedery B, Povoa M, et al. (2001) Plasmodium vivax merozoite surface proteins-3beta and-3gamma share structural similarities with P. vivax merozoite surface protein-3alpha and define a new gene family. Mol Biochem Parasitol 115: 41–53.
- Lima-Junior JC, Jiang J, Rodrigues-da-Silva RN, Banic DM, Tran TM, et al. (2011) B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3alpha (PvMSP-3alpha) in malaria exposed individuals from Brazilian Amazon. Vaccine 29: 1801–1811.

Acknowledgments

We would like to thank Nora Martínez and especially Jason Garry for extensively reviewing this manuscript, as well as Gabriela Arévalo and Darwin Andrés Moreno for their technical support.

Author Contributions

Conceived and designed the experiments: DRM DB MEP MAP LFN. Performed the experiments: DRM DB JGCP AM. Analyzed the data: DRM DB JGCP AM MEP MAP LFN. Contributed reagents/materials/ analysis tools: DRM DB. Wrote the paper: DRM DB JGCP AM MEP MAP.

- Mittra P, Singh N, Sharma YD (2010) Plasmodium vivax: immunological properties of tryptophan-rich antigens PvTRAg 35.2 and PvTRAg 80.6. Microbes Infect 12: 1019–1026.
- Son ES, Kim TS, Nam HW (2001) Western blot diagnosis of vivax malaria with multiple stage-specific antigens of the parasite. Korean J Parasitol 39: 171–176.
- Rojas-Caraballo J, Mongui A, Giraldo MA, Delgado G, Granados D, et al. (2009) Immunogenicity and protection-inducing ability of recombinant Plasmodium vivax rhoptry-associated protein 2 in Aotus monkeys: a potential vaccine candidate. Vaccine 27: 2870–2876.
- Sierra AY, Barrero CA, Rodriguez R, Silva Y, Moncada C, et al. (2003) Splenectomised and spleen intact Aotus monkeys' immune response to Plasmodium vivax MSP-1 protein fragments and their high activity binding peptides. Vaccine 21: 4133–4144.
- Galinski MR, Medina CC, Ingravallo P, Barnwell JW (1992) A reticulocytebinding protein complex of Plasmodium vivax merozoites. Cell 69: 1213–1226.
- Urquiza M, Patarroyo MA, Mari V, Ocampo M, Suarez J, et al. (2002) Identification and polymorphism of Plasmodium vivax RBP-1 peptides which bind specifically to reticulocytes. Peptides 23: 2265–2277.
- Arevalo-Pinzon G, Curtidor H, Patino LC, Patarroyo MA (2011) PvRON2, a new Plasmodium vivax rhoptry neck antigen. Malar J 10: 60.
- Mongui A, Perez-Leal O, Soto SC, Cortes J, Patarroyo MA (2006) Cloning, expression, and characterisation of a Plasmodium vivax MSP7 family merozoite surface protein. Biochem Biophys Res Commun 351: 639–644.
- Perez-Leal O, Mongui A, Cortes J, Yepes G, Leiton J, et al. (2006) The Plasmodium vivax rhoptry-associated protein 1. Biochem Biophys Res Commun 341: 1053–1058.
- Sugiyama T, Suzue K, Okamoto M, Inselburg J, Tai K, et al. (1996) Production of recombinant SERA proteins of Plasmodium falciparum in Escherichia coli by using synthetic genes. Vaccine 14: 1069–1076.
- Llinas M, del Portillo HA (2005) Mining the malaria transcriptome. Trends Parasitol 21: 350–352.
- Lamarque M, Besteiro S, Papoin J, Roques M, Vulliez-Le Normand B, et al. (2011) The RON2-AMA1 interaction is a critical step in moving junctiondependent invasion by apicomplexan parasites. PLoS Pathog 7: e1001276.
- Rodriguez LE, Curtidor H, Urquiza M, Cifuentes G, Reyes C, et al. (2008) Intimate molecular interactions of P. falciparum merozoite proteins involved in invasion of red blood cells and their implications for vaccine design. Chem Rev 108: 3656–3705.
- Chen Z, Harb OS, Roos DS (2008) In silico identification of specialized secretory-organelle proteins in apicomplexan parasites and in vivo validation in Toxoplasma gondii. PLoS One 3: e3611.
- Kats LM, Cooke BM, Coppel RL, Black CG (2008) Protein trafficking to apical organelles of malaria parasites - building an invasion machine. Traffic 9: 176–186.
- Richard D, Kats LM, Langer C, Black CG, Mitri K, et al. (2009) Identification of rhoptry trafficking determinants and evidence for a novel sorting mechanism in the malaria parasite Plasmodium falciparum. PLoS Pathog 5: e1000328.
- Gilson PR, Nebl T, Vukcevic D, Moritz RL, Sargeant T, et al. (2006) Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum. Mol Cell Proteomics 5: 1286–1299.
- Sanders PR, Cantin GT, Greenbaum DC, Gilson PR, Nebl T, et al. (2007) Identification of protein complexes in detergent-resistant membranes of Plasmodium falciparum schizonts. Mol Biochem Parasitol 154: 148–157.
- Sanders PR, Gilson PR, Cantin GT, Greenbaum DC, Nebl T, et al. (2005) Distinct protein classes including novel merozoite surface antigens in Raft-like membranes of Plasmodium falciparum. J Biol Chem 280: 40169–40176.
- Crompton PD, Pierce SK, Miller LH (2010) Advances and challenges in malaria vaccine development. J Clin Invest 120: 4168–4178.
- Poisson G, Chauve C, Chen X, Bergeron A (2007) FragAnchor: a large-scale predictor of glycosylphosphatidylinositol anchors in eukaryote protein sequences by qualitative scoring. Genomics Proteomics Bioinformatics 5: 121–130.

P. vivax Vaccine Candidate Selection Using HMMs

- Finn RD, Mistry J, Tate J, Coggill P, Heger A, et al. (2010) The Pfam protein families database. Nucleic Acids Res 38: D211–222.
- Hunter S, Apweiler R, Attwood TK, Bairoch A, Bateman A, et al. (2009) InterPro: the integrative protein signature database. Nucleic Acids Res 37: D211–215.
- Ansari FA, Kumar N, Bala Subramanyam M, Gnanamani M, Ramachandran S (2008) MAAP: malarial adhesins and adhesin-like proteins predictor. Proteins 70: 659–666.
- Isokpehi RD (2007) Data Mining of Malaria Parasite Gene Expression for Possible Translational Research. Methods of Microarray Data Analysis V: 1–10.
- Ginsburg H (2006) Progress in in silico functional genomics: the malaria Metabolic Pathways database. Trends Parasitol 22: 238–240.
- Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, et al. (2007) Clustal W and Clustal X version 2.0. Bioinformatics 23: 2947.
- Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, et al. (2003) The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol 1: E5.
- Aurrecoechea C, Brestelli J, Brunk BP, Dommer J, Fischer S, et al. (2009) PlasmoDB: a functional genomic database for malaria parasites. Nucleic Acids Res 37: D539–543.

- Garg A, Raghava GP (2008) ESLpred2: improved method for predicting subcellular localization of eukaryotic proteins. BMC Bioinformatics 9: 503.
- Pierleoni A, Martelli PL, Fariselli P, Casadio R (2006) BaCelLo: a balanced subcellular localization predictor. Bioinformatics 22: e408–416.
- Bendtsen JD, Nielsen H, von Heijne G, Brunak S (2004) Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 340: 783–795.
- Kall L, Krogh A, Sonnhammer EL (2005) An HMM posterior decoder for sequence feature prediction that includes homology information. Bioinformatics 21(Suppl 1): i251–257.
- Bendtsen JD, Jensen LJ, Blom N, von Heijne G, Brunak S (2004) Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng Des Sel 17: 349–356.
- Krogh A, Larsson B, von Heijne G, Sonnhammer EL (2001) Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. J Mol Biol 305: 567–580.
- Wakaguri H, Suzuki Y, Sasaki M, Sugano S, Watanabe J (2009) Inconsistencies of genome annotations in apicomplexan parasites revealed by 5'-end-one-pass and full-length sequences of oligo-capped cDNAs. BMC Genomics 10: 312.